Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

(1,706) (1,212) Selling expenses (223) (222) Other operating income 2,092 33 OPERATING RESULT (5,524) 17,286 Financial income 1,033 1,022 Financial expenses (179) (190) Result before income tax (4,670) 18,118 Income tax 7 (90) Net result for the period (4,663) 18,028 Attributable to: Equity holders of the company (4,663) 18,028 Result per share Basic earnings per share {Euro} (0.18) 0.72 Diluted earnings per share {Euro} (0.17) 0.67 Unaudited consolidated statement of comprehensive income ThromboGenics Unaudited consolidated statement of other comprehensive income Half year Half year In '000 Euro - According to IFRS 6 months 6 months Jan - June 2009 Jan - June 2008 Available-for-sales investments Valuation gain/(loss) taken to equity 72 (58) Exchange differences on translation of foreign operations 11 4 Other comprehensive income net of tax 83 (54) Total result for the period (4,663) 18,028 Total comprehensive income (4,580) 17,974 Attributable to: Equity holders of the parent (4,580) 17,974 Unaudited consolidated statement of financial position ThromboGenics
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... San Diego, CA (PRWEB) December 17, 2014 ... strategy and activation agency and member of the Huntsworth ... Jamie Gonzales to its executive team. In her role, ... Services. , “We are incredibly honored to welcome ... said Agency Chief and CEO, Gaëtan Fraikin. “She is ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology,  today celebrated continued positive ... exVive3D TM Human Liver Tissue.  The product, ... release on November 18, has been recognized as ... for innovation. Most recently, on December ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... Dec. 1 Collexis Holdings, Inc.,(OTC Bulletin ... search and,knowledge discovery software, announced today a ... to promote BiomedExperts.com,to the association,s 200+ membership ... the primary professional network for,BioFlorida, helping to ...
... ISIS ) announces the following webcast: , , ... of a, microRNA, ... 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT, Where: ... Simply log onto our website listed above., , ...
... a California company aided in the research of vein treatment methods led ... equipment to develop a new medical device, which he will present this ... ... (PRWEB) December 1, 2008-- A gift from a California company aided in ...
Cached Biology Technology:BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 3BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 4Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... peak supercomputer at the Department of Energy,s Pacific Northwest ... research in areas such as energy storage and future ... similar computers because of its unique water cooling system. ... about 20,000 typical personal computers combined, the Olympus supercomputer ...
... 2012 BGI, the world,s largest genomics organization, announced today ... for Soybean Biotechnology at the University of Missouri to ... contract in 2012 to re-sequence the first 100 lines ... agreement, BGI will provide library construction, re-sequencing analysis, 5X ...
... appears in toddlers just as they are beginning to walk ... energy-producing power plants of cells. This finding by a team ... and Hospital The Neuro- at McGill University, was published ... National Academy of Sciences of the USA ( PNAS ...
Cached Biology News:PNNL's Olympus supercomputer advances science, saves energy 2PNNL's Olympus supercomputer advances science, saves energy 3BGI enters agreement with National Center for Soybean Biotechnology to re-sequence 1,008 soybean lines 2BGI enters agreement with National Center for Soybean Biotechnology to re-sequence 1,008 soybean lines 3Defective cell 'battery' plays central role in neurodegenerative disease 2
... serum is extensively scrutinized, including ... All horses are of ... worming are controlled and documented ... consistency. Pricing: $12/unit ...
... new primer sets added in Dec 2005 ... hours , Detection from as little ... Specific primers available for hundreds of mammalian ... or end-point RT-PCR , Ideal for ...
jub, ajuba homolog (Xenopus laevis)...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: